These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 33850839)
1. Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany. Teich N; Bläker M; Holtkamp-Endemann F; Jörgensen E; Stallmach A; Hohenberger S Inflamm Intest Dis; 2021 Feb; 6(1):48-60. PubMed ID: 33850839 [TBL] [Abstract][Full Text] [Related]
2. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease. Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216 [TBL] [Abstract][Full Text] [Related]
3. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months. Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S BMC Gastroenterol; 2021 Apr; 21(1):161. PubMed ID: 33845784 [TBL] [Abstract][Full Text] [Related]
4. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. Claudepierre P; Van den Bosch F; Sarzi-Puttini P; Vastesaeger N; Govoni M; Kachroo S Int J Rheum Dis; 2019 Jun; 22(6):995-1001. PubMed ID: 30989813 [TBL] [Abstract][Full Text] [Related]
5. [A comparative study of induction of remission and cost-effectiveness of enteral nutrition versus infliximab in moderate-to-severe Crohn's disease]. Zhu WM; Zuo LG; Li Y; Cao L; Zhang W; Gu YF; Xu M; Li N; Li JS Zhonghua Nei Ke Za Zhi; 2013 Sep; 52(9):721-5. PubMed ID: 24314158 [TBL] [Abstract][Full Text] [Related]
6. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. Bhatia JK; Korelitz BI; Panagopoulos G; Lobel E; Mirsky F; Sultan K; DiSanti W; Chun A; Keenan G; Mamun K J Clin Gastroenterol; 2007 Aug; 41(7):677-81. PubMed ID: 17667052 [TBL] [Abstract][Full Text] [Related]
7. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478 [TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease. Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105 [TBL] [Abstract][Full Text] [Related]
9. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Yoshida K; Fukunaga K; Ikeuchi H; Kamikozuru K; Hida N; Ohda Y; Yokoyama Y; Iimuro M; Takeda N; Kato K; Kikuyama R; Nagase K; Hori K; Nakamura S; Miwa H; Matsumoto T Inflamm Bowel Dis; 2012 Sep; 18(9):1617-23. PubMed ID: 22081474 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J; Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899 [TBL] [Abstract][Full Text] [Related]
11. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Lichtenstein GR; Yan S; Bala M; Hanauer S Am J Gastroenterol; 2004 Jan; 99(1):91-6. PubMed ID: 14687148 [TBL] [Abstract][Full Text] [Related]
12. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. Louis E; Löfberg R; Reinisch W; Camez A; Yang M; Pollack PF; Chen N; Chao J; Mulani PM J Crohns Colitis; 2013 Feb; 7(1):34-43. PubMed ID: 22480772 [TBL] [Abstract][Full Text] [Related]
13. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Reilly MC; Gerlier L; Brabant Y; Brown M Clin Ther; 2008 Feb; 30(2):393-404. PubMed ID: 18343277 [TBL] [Abstract][Full Text] [Related]
14. P016 Impact of Non-Remission on Health-Related Quality of Life and Patient Reported Outcomes in Patients With Crohn's Disease: Targeted Literature Review. Thakur D; Chatziandreou K; Sanon M; Naessens D; Atanasov P Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S4. PubMed ID: 37461936 [TBL] [Abstract][Full Text] [Related]
15. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. Viola A; Costantino G; Privitera AC; Bossa F; Lauria A; Grossi L; Principi MB; Della Valle N; Cappello M World J Gastrointest Pharmacol Ther; 2017 May; 8(2):131-136. PubMed ID: 28533923 [TBL] [Abstract][Full Text] [Related]
16. Visceral adiposity and inflammatory bowel disease. Rowan CR; McManus J; Boland K; O'Toole A Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989 [TBL] [Abstract][Full Text] [Related]
17. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. Tajiri H; Motoya S; Kinjo F; Maemoto A; Matsumoto T; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T PLoS One; 2018; 13(8):e0201956. PubMed ID: 30114224 [TBL] [Abstract][Full Text] [Related]
18. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. Buhl SS; Steenholdt C; Brynskov J; Thomsen OØ; Bendtzen K; Ainsworth MA BMJ Open; 2014 Dec; 4(12):e005887. PubMed ID: 25524543 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study. Miheller P; Lakatos PL; Horváth G; Molnár T; Szamosi T; Czeglédi Z; Salamon A; Czimmer J; Rumi G; Palatka K; Papp M; Jakab Z; Szabó A; Gelley A; Lakatos L; Barta Z; Balázs C; Rácz I; Zeher M; Döbrönte Z; Altorjay I; Hunyady B; Simon L; Papp J; Banai J; Nagy F; Lonovics J; Ujszászy L; Muzes G; Herszényi L; Tulassay Z BMC Gastroenterol; 2009 Sep; 9():66. PubMed ID: 19740450 [TBL] [Abstract][Full Text] [Related]
20. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]